Efficacy of HPV-based screening for prevention of invasive cervical cancer: Follow-up of four European randomised controlled trials

The Lancet

Volumn 383, Issue 9916, 2014, Pages 524-532

  Ronco, Guglielmo ^a   Dillner, Joakim ^c   Elfström, K Miriam ^c   Tunesi, Sara ^a   Snijders, Peter J F ^d   Arbyn, Marc ^e   Kitchener, Henry ^f   Segnan, Nereo ^a,b   Gilham, Clare ^h   Giorgi Rossi, Paolo ^g   Berkhof, Johannes ^d   Peto, Julian ^h   Meijer, Chris J L M ^d   Cuzick, Jack ⁱ   Zappa, Marco ^j   Carozzi, Francesca ^j   Confortini, Massimo ^j   Dalla Palma, Paolo ^k   Zorzi, Manuel ^l   Del Mistro, Annarosa ^l   Gillio Tos, Anna ^m   Naldoni, Carlo ⁿ   Rijkaart, Dorien ^d   Van Kemenade, Folkert ^d   Bulkmans, Nicole ^d   Heideman, Danielle ^d   Rozendaal, Rence ^d   Kenter, Gemma ^d   Almonte, Maribel ^b   Roberts, Christopher ^o   Desai, Mina ^p   Sargent, Alexandra ^p   Ryd, Walter ^q   Naucler, Pontus ^c   more..

^a CITTÀ DELLA SALUTE E DELLA SCIENZA HOSPITAL   (Italy)

^b INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^c KAROLINSKA INSTITUTE   (Sweden)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^e SCIENTIFIC INSTITUTE OF PUBLIC HEALTH   (Belgium)

^f UNIVERSITY OF MANCHESTER   (United Kingdom)

^g Azienda Sanitaria Locale   (Italy)

^h LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

ⁱ QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^j Istituto per lo Studio e la Prevenzione Oncologica   (Italy)

^k SANTA CHIARA HOSPITAL   (Italy)

^l VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^m UNIVERSITY OF TURIN   (Italy)

ⁿ Emila Romagna Region   (Italy)

^o UNIVERSITY OF MANCHESTER   (United Kingdom)

^p MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^q SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CANCER INCIDENCE; CANCER PREVENTION; CANCER REGISTRY; CANCER SCREENING; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; HUMAN PAPILLOMAVIRUS BASED SCREENING; MAJOR CLINICAL STUDY; MIDDLE AGED; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); UTERINE CERVIX CARCINOMA; YOUNG ADULT;

EID: 84895909567     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(13)62218-7     Document Type: Article

References (28)

1. Sankaranarayanan R, Nene BM, Shastri SS, et al. HPV screening for cervical cancer in rural India. N Engl J Med 2009; 360: 1385-94.
2. Naucler P, Ryd W, Törnberg S, et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med 2007; 357: 1589-97.
3. Bulkmans NW, Berkhof J, Rozendaal L, et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 2007; 370: 1764-72.
4. Rijkaart DC, Berkhof J, Rozendaal L, et al. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncol 2012; 13: 78-88.
5. Kitchener HC, Almonte M, Thomson C, et al. HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial. Lancet Oncol 2009; 10: 672-82.
6. Ronco G, Giorgi-Rossi P, Carozzi F, et al, and the New Technologies for Cervical Cancer screening (NTCC) Working Group. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol 2010; 11: 249-57.
7. Arbyn M, Ronco G, Anttila A, et al. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine 2012; 30 (suppl 5): F88-99.
8. Elfgren K, Rylander E, Rådberg T, et al, and the Swedescreen Study Group. Colposcopic and histopathologic evaluation of women participating in population-based screening for human papillomavirus deoxyribonucleic acid persistence. Am J Obstet Gynecol 2005; 193: 650-57.
9. Bulkmans NW, Rozendaal L, Snijders PJ, et al. POBASCAM, a population-based randomized controlled trial for implementation of high-risk HPV testing in cervical screening: design, methods and baseline data of 44,102 women. Int J Cancer 2004; 110: 94-101.
10. Kitchener HC, Almonte M, Wheeler P, et al, and the ARTISTIC Trial Study Group. HPV testing in routine cervical screening: cross sectional data from the ARTISTIC trial. Br J Cancer 2006; 95: 56-61.
11. Ronco G, Segnan N, Giorgi-Rossi P, et al, and the New Technologies for Cervical Cancer Working Group. Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial. J Natl Cancer Inst 2006; 98: 765-74.
12. Ronco G, Giorgi-Rossi P, Carozzi F, et al, and the New Technologies for Cervical Cancer screening Working Group. Human papillomavirus testing and liquid-based cytology in primary screening of women younger than 35 years: results at recruitment for a randomised controlled trial. Lancet Oncol 2006; 7: 547-55.
13. Ronco G, Giorgi-Rossi P, Carozzi F, et al, and the New Technologies for Cervical Cancer Screening Working Group. Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test. J Natl Cancer Inst 2008; 100: 492-501.
14. Solomon D, Davey D, Kurman R, et al, and the Forum Group Members, and the Bethesda 2001 Workshop. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 2002; 287: 2114-19.
15. Jacobs MV, Snijders PJ, van den Brule AJ, Helmerhorst TJ, Meijer CJ, Walboomers JM. A general primer GP5+/GP6(+)-mediated PCR-enzyme immunoassay method for rapid detection of 14 high-risk and 6 low-risk human papillomavirus genotypes in cervical scrapings. J Clin Microbiol 1997; 35: 791-95.
16. Parkin DM, Shanmugaratnam K, Sobin L, Ferlay J, Whelan SL. Histological groups for comparative studies: technical report no 31. Lyon: IARC, 1998.
17. Dalla Palma P, Giorgi Rossi P, Collina G, et al, and the NTCC Pathology Group. The reproducibility of CIN diagnoses among different pathologists: data from histology reviews from a multicenter randomized study. Am J Clin Pathol 2009; 132: 125-32.
18. Rothman KJ. Estimation of confidence limits for the cumulative probability of survival in life table analysis. J Chronic Dis 1978; 31: 557-60.
19. Breslow NE, Day NE. Statistical methods in cancer research: vol II-the design and analysis of cohort studies. Lyon: IARC Scientific Publications, 1987.
20. Greenland S. Quantitative methods in the review of epidemiologic literature. Epidemiol Rev 1987; 9: 1-30.
21. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 1539-58.
22. Mayrand MH, Duarte-Franco E, Rodrigues I, et al, and the Canadian Cervical Cancer Screening Trial Study Group. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med 2007; 357: 1579-88.
23. Ogilvie GS, Krajden M, van Niekerk DJ, et al. Primary cervical cancer screening with HPV testing compared with liquid-based cytology: results of round 1 of a randomised controlled trial-the HPV FOCAL Study. Br J Cancer 2012; 107: 1917-24.
24. Leinonen MK, Nieminen P, Lönnberg S, et al. Detection rates of precancerous and cancerous cervical lesions within one screening round of primary human papillomavirus DNA testing: prospective randomised trial in Finland. BMJ 2012; 345: e7789.
25. Zappa M, Ciatto S. Cervix cancer: case-control studies on screening. In: Sankila R, Demaret E, Hakama M, Lynge E, Schouten LJ, Parkin DM, eds. Evaluation and monitoring of screening programmes. Brussels: Europe Against Cancer Programme, 2000: 99-118.
26. Andrae B, Kemetli L, Sparén P, et al. Screening-preventable cervical cancer risks: evidence from a nationwide audit in Sweden. J Natl Cancer Inst 2008; 100: 622-29.
27. Sasieni P, Castanòn A, Cuzick J. Effectiveness of cervical screening with age: population based case-control study of prospectively recorded data. BMJ 2009; 339: b2968.
28. Rodríguez AC, Schiffman M, Herrero R, et al. Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection. J Natl Cancer Inst 2010; 102: 315-24.